



## NHIA BAMLANIVIMAB PILOT PROGRAM

NHIA is working with the Department of Health and Human Services (HHS) to increase access to bamlanivimab (Eli Lilly) for COVID-19 in high-risk, eligible individuals residing or working in long-term care facilities, including assisted living facilities. Through this pilot, NHIA is part of HHS' Special Projects for Equitable and Efficient Distribution (SPEED) program.

The program utilizes home infusion providers - in partnership with facility staff - to identify, assess, coordinate, dispense, and administer monoclonal antibody therapies in these healthcare settings. The duration of the program is dependent on interest from home infusion providers and facilities, as well as early results demonstrating program goals are being met.

This pilot program is intended to accomplish two main goals:

1. Expand access to bamlanivimab to the patients at highest risk for hospitalization and complications who reside in long-term care facilities; and
2. Identify qualified home infusion providers that are interested in working directly with states to provide COVID-19 treatments in other settings.

NHIA will be responsible for working with HHS to allocate 500 doses per week beginning December 8, 2020. Home infusion providers who wish to participate in the program and meet the eligibility criteria will be listed on a publicly accessible database for states to reference for future COVID-19 treatment opportunities.

The program is open to both NHIA member and non-member provider organizations, provided they qualify. In order to participate, a provider must:

- Be a licensed pharmacy in good standing
- Be accredited in home infusion
- Be enrolled with the Centers for Medicare and Medicaid Services (CMS) as a pharmacy or vaccine/immunization provider
- Be able to perform patient assessments for eligibility per the Emergency Use Authorization, obtain physician orders, coordinate nursing services for administration, dispense, and deliver the product
- Make every effort to perform infusions within 24 hours of receiving a qualified referral
- Be able to collect and submit required data

To enroll in the pilot, home infusion providers will need to fill out an online application and sign a participation agreement. For more information and links, visit

<https://www.nhia.org/news/bam-pilot-program/>.

